As per the research report, the size of the Middle east and Africa HIV Diagnostics Market is valued USD 247.99 million in 2022 and estimated to be growing at a CAGR of 7.82%, to reach 361.35 million by 2027 during the forecast period 2022 to 2027.
The MEA market is predicted to develop due to factors such as the rising prevalence of HIV, the rising number of blood transfusions and blood donations, the benefits provided by point-of-care tools and kits, and increased government initiatives. The presence of important companies, the high prevalence of HIV in the region, and developed healthcare infrastructure are some of the key factors contributing to the market's huge share.
The unprecedented efforts of many social organisations to raise awareness about HIV and its symptoms, as well as to encourage people to get regular blood tests, will help the HIV diagnostics market expand. In comparison to the North African region, HIV prevalence in Africa, particularly in the Southern region, is quite high. HIV affects about one out of every four people. The Southern and Eastern African regions have one of the highest HIV prevalence rates, with around 20 million individuals infected. While the prevalence of HIV is low in North Africa, the number of HIV cases is constantly increasing.
When the Middle East and African HIV Diagnosis and Treatment markets are considered, Africa is thought to be the largest market for HIV Diagnosis and Treatment. Furthermore, the Rest of the Middle East and Africa is expanding, and it is now the second largest market for HIV Diagnosis and Treatment in the Middle East and Africa.
Saudi Arabia's market growth will most likely be limited yet moderate. The lack of nucleic acid test mandates in this nation is a key restriction to market expansion.
This research report on the Middle East & Africa HIV Diagnostics Market has been segmented and sub-segmented into the following categories:
By End User:
The market is being boosted by the efficacy of antigen testing, an increase in government initiatives and programmes. African chiefs of state, for example, have approved two significant new programmes efforts to eliminate AIDS/HIV by 2030. The Western and Central Africa Catch-up Plan intends to reduce the gap in HIV treatment access between African regions by accelerating access to HIV treatment in the region. Increasing government initiatives to raise knowledge about HIV disease prevention and treatment options.
Initially, HIV prevention efforts primarily focused on changing behaviour to avoid HIV transmission through sexual contact. Chronic diseases have a significant impact on the Middle East and Africa region. The lack of a functioning healthcare system in African countries, as well as a lack of awareness of novel disease diagnosis tools, are the primary causes of this escalating burden. The country with the largest number of HIV-positive people is South Africa.It was seen that NCDs (Non Communicable Diseases) such as heart disease, stroke, cancer, diabetes, and chronic lung disease were on the rise in South Africa.
The African region is expected to have a significant need for diagnostics as a result of the rising burden of chronic diseases, which is a result of a lack of adequate diagnosis. The United Arab Emirates and Saudi Arabia are primarily medical tourism destinations, and as a result, they are the most important locations in the Middle East and Africa region for many industries.
The leading companies leading in the MEA HIV diagnostics Market profiled in the report are Abbott Healthcare, Brsitol-Myers Squibb, Abbvie Inc., Alere Inc., Gilead Sciences, Merck & Co. Inc, Janssen Therapeutics, BD Biosciences, VIIV Healthcare, Partec, Sysmex, Beckman Coulter, Apogee Flow Systems, Zyomyx Inc., PointCare Technologies Inc., Mylan inc., Qiagen, Roche Diagnostics, Siemens Healthcare, and bioMerieux.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com